Discover
KROS
Keros Therapeutics, Inc.
11.95
2 x 7.33
2 x 13.08
bid
ask
+
0.31
2.66%
2 @ 05:42 PM
11.95 +0.00 (0.00%)
| Ytd | -41.31% | |
| 1y | -25.87% |
11.49
day range
12.24
9.91
52 week range
21.84
| Open | 11.58 | Prev Close | 11.64 | Low | 11.49 | High | 12.24 | Mkt Cap | 236.93M |
| Vol | 194.39K | Avg Vol | 194.05K | EPS | -3.22 | P/E | N/A | Forward P/E | -3.00 |
| Beta | 1.24 | Short Ratio | 5.28 | Inst. Own | 100.86% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 11.04 | 200-d Avg | 12.73 | 1yr Est | 43.55 |
| Income Statement | |||
| Operating Expenses | 30.94M | ||
| Research and Development Expense | 22.33M | ||
| Selling, General and Administrative Expense | 8.61M | ||
| Operating Income | -30.94M | ||
| Net Income | -28.71M | ||
| Net Income Common Stock | -28.71M | ||
| Net Income Common Stock (USD) | -28.71M | ||
| Consolidated Income | -28.71M | ||
| Earnings per Basic Share | -1.45 | ||
| Earnings per Basic Share (USD) | -1.45 | ||
| Earnings per Diluted Share | -1.45 | ||
| Earning Before Interest & Taxes (EBIT) | -28.71M | ||
| Earning Before Interest & Taxes (USD) | -28.71M | ||
| Weighted Average Shares | 19.80M | ||
| Weighted Average Shares Diluted | 19.80M | ||
| Balance Sheet | |||
| Cash and Equivalents | 259.06M | ||
| Cash and Equivalents (USD) | 259.06M | ||
| Current Assets | 266.88M | ||
| Property, Plant & Equipment Net | 19.27M | ||
| Total Assets | 287.60M | ||
| Debt Current | 2.60M | ||
| Total Debt | 15.72M | ||
| Current Liabilities | 12.15M | ||
| Debt Non-Current | 13.13M | ||
| Total Liabilities | 25.28M | ||
| Accumulated Retained Earnings (Deficit) | -534.18M | ||
| Shareholders Equity | 262.32M | ||
| Shareholders Equity (USD) | 262.32M | ||
| Assets Non-Current | 20.72M | ||
| Total Debt (USD) | 15.72M | ||
| Liabilities Non-Current | 13.13M | ||
| Trade and Non-Trade Payables | 1.82M | ||
| Tax Assets | 2.25M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.05M | ||
| Net Cash Flow from Financing | -3.31M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -23.89M | ||
| Capital Expenditure | -155.00K | ||
| Issuance (Purchase) of Equity Shares | 23.00K | ||
| Net Cash Flow from Investing | -155.00K | ||
| Net Cash Flow from Operations | -20.42M | ||
| Share Based Compensation | 5.38M | ||